Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of Type 2 diabetes mellitus(T2DM) prior to informed consent~2. Male and female patients on diet and exercise regimen who are drug-naïve~3. Glycosylated haemoglobin A1c (HbA1c) at V1a \>/=7.5 %\<11% for main group and HbA1c \>/= 11.0 % for the additional parallel group~4. Age \>/= 18 and \</= 80 years at Visit 1a (Screening)~5. Body Mass Index(BMI)\</ = 40 kg/m2 at Visit 1a (Screening)~6. Signed and dated written informed consent by date of Visit 1a in accordance with good clinical practice(GCP) and local legislation~Exclusion criteria:~1. Uncontrolled hyperglycaemia required for rescue medication during placebo run-in phase~2. In main group, the patients with investigational medicinal product(IMP) compliance \< 80 % or \>120 % during 2 weeks placebo run in period~3. Acute coronary syndrome stroke or Transient ischaemic attack (TIA) within 3 months prior to randomisation~4. Impaired hepatic function, defined by serum levels of either Alanine aminotransferase(ALT) ,Aspartate aminotransferase(AST), or alkaline phosphatase (AP) above 3 x upper limit of normal (ULN) ,or total bilirubin above 1.5 x ULN as determined at Visit 1a~5. Known hypersensitivity or allergy to linagliptin or its excipients or metformin or placebo~6. Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at the time of screening~7. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.~8. Concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing the consent form or during the trial.~9. Pre-menopausal women (last menstruation \</= 1 year prior to informed consent) who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study~10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.~11. Renal failure or renal impairment at Visit 1a (screening) with an Estimated Glomerular Filtration Rate(eGFR) \< 60 ml/min~12. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption~13. Dehydration by clinical judgement of the investigator~14. Clinical detected unstable or acute congestive heart failure~15. Acute or chronic metabolic acidosis (present in patient history)~16. Hereditary galactose intolerance~17. Known history of pancreatitis and chronic pancreatitis~18. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within last 5 years.~19. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial at the discretion of investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- linagliptin2.5mg / metformin500mg BID (Type: EXPERIMENTAL): patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
- linagliptin2.5mg / metformin1000mg BID (Type: EXPERIMENTAL): patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
- metformin 500mg BID (Type: ACTIVE_COMPARATOR): patient to receive a tablet containing metformin 500mg BID
- metformin 1000mg BID (Type: ACTIVE_COMPARATOR): patient to receive a tablet containing metformin 1000mg BID
- linagliptin 5 mg QD (Type: ACTIVE_COMPARATOR): patient to receive a tablet containing linagliptin 5mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).